TABLE 3.

Summary of TEAEs

	All cenobamate, N = 240, n (%)	Continuing cenobamate at data cutoff, N = 177, n (%)
Patients with ≥1 TEAE	236 (98.3)	175 (98.9)
Serious TEAEs	50 (20.8)	36 (20.3)
TEAEs in ≥10% of patients
Fatigue	83 (34.6)	67 (37.9)
Dizziness	77 (32.1)	59 (33.3)
Somnolence	71 (29.6)	53 (29.9)
Upper respiratory tract infection	38 (15.8)	34 (19.2)
Balance disorder	37 (15.4)	29 (16.4)
Headache	36 (15.0)	29 (16.4)
Nausea	28 (11.7)	24 (13.6)
Fall	25 (10.4)	18 (10.2)
Weight decreased	24 (10.0)	18 (10.2)

Abbreviation: TEAE, treatment‐emergent adverse event.